TSPAN6 and central nervous system cancer: Meanwhile, the use of pan-cancer analysis revealed that TSPAN6 expression could serve as a promising prognostic biomarker for glioma patients, as indicated by the COX regression analysis (overall survival: HR = 2.42, p = 7.7e-17; disease-specific survival: HR = 2.55, p = 2.5e-16; progression-free survival: HR = 1.88, p = 8.7e-13; Figure S1-3).